Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma

Cancer Control

Volumn 9, Issue 3, 2002, Pages 203-211

  Chrischilles, Elizabeth ^a   Delgado, David J ^b   Stolshek, Bradley S ^b   Lawless, Grant ^b   Fridman, Moshe ^c   Carter, William B ^b  

^a UNIVERSITY OF IOWA   (United States)

^b AMGEN INC   (United States)

^c AMF Consulting Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; COMORBIDITY; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PROPHYLAXIS;

EID: 0036080490     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200900303     Document Type: Article

References (40)

1. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking
2. Cancer statistics, 2002
3. The National Cancer Data Base report on non-Hodgkin's lymphoma
4. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
5. CHOP is curative in thirty percent of patients with large cell lymphoma: A twelve-year Southwest Oncology Group follow-up
6. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma
7. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
8. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience
9. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma
10. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis
11. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol
12. Factors affecting reduced survival of the elderly with intermediate grade lymphoma: An analysis of SWOG-8516(INT 0067) - The national high priority lymphoma study - A randomized comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B
13. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age
14. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis
15. Granulocyte-colony stimulating factor (G-CSF) may improve disease outcomes in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy
16. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
17. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia
18. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium
19. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer
20. CHOP chemotherapy with G-CSF in elderly patients with intermediate grade lymphoma (IGL): Full dose intensity is possible
21. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma
22. Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients
23. Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma
24. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: A risk factor analysis
25. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
26. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
27. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives
28. Report of the Committee on Hodgkin's Disease Staging Classification
29. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project
30. The importance of dose intensity in chemotherapy of metastatic breast cancer
31. The geriatric cancer patient: Equal benefit from equal treatment
32. Current guidelines for the management of aggressive non-Hodgkin's lymphoma
33. Non-Hodgkin's lymphoma in the elderly: A guide to treatment
34. Impacts of geriatric evaluation and management programs on defined outcomes: Overview of the evidence
35. J. NEUPOGEN ® (r-metHuG-CSF) ameliorates neutropenia during CHOP chemotherapy
36. Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
37. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidenced-based clinical practice guidelines
38. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
39. Hematopoietic growth factors in the older cancer patient
40. Geriatric oncology: Challenges for the new century